The practical relevance of our results was corroborated by the findings that KDM6A together with TRKA were upregulated in patient-derived CML cells, and in particular, KDM6A was further increased in CML samples from imatinib-resistant individuals. This evidence concerns the gene NTRK1 and chronic myelogenous leukemia, BCR-ABL1 positive.